German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.
List view / Grid view
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
CRISPR holds great promise in advancing pharmacological research and has fuelled the rapid expansion of using gene-edited cells for drug discovery processes. CRISPR-Cas9 dropout screens have emerged as a useful tool for high-throughput large-scale loss-of-function screens, which seek to identify the relationship between genotype and phenotype. Dr Pushpanathan Muthuirulan, Research…
Interleukin 13 receptor alpha 2 was found in increased rates in cancer cells that metastasised to the brain and lungs, a new study has shown.
In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
Research by a team in Canada reveals a promising therapeutic target to counter HER2-positive breast cancer.
Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
Researchers have measured the gene expression of healthy and cancerous single cells from breast tissue, creating an 'RNA atlas'.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
A range of imaging and computational techniques were used by researchers to discover the structure of the PH domain of PLEKHA7.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
A team have shown that a tumour-suppressing and killing molecule delivered to the brain by stem cells has been successful in mice.
A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.